Hot Features
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II clinical trial for the treatment of peripheral arterial disease, chronic limb t... Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II clinical trial for the treatment of peripheral arterial disease, chronic limb threatening ischemia, cardiovascular ischemia and angina, and vascular dementia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.04968 | 0.04968 | 0.04968 | 1000 | 0.04968 | CS |
| 4 | 0.00768 | 18.2857142857 | 0.042 | 0.04968 | 0.03744 | 9909 | 0.03965231 | CS |
| 12 | 0.004608 | 10.2236421725 | 0.045072 | 0.0521 | 0.035 | 13761 | 0.04003567 | CS |
| 26 | -0.01022 | -17.061769616 | 0.0599 | 0.07618 | 0.035 | 13591 | 0.05222069 | CS |
| 52 | -0.05202 | -51.1504424779 | 0.1017 | 0.11 | 0.035 | 17144 | 0.06853357 | CS |
| 156 | -0.03862 | -43.7372593431 | 0.0883 | 0.285 | 0.024 | 27162 | 0.10282494 | CS |
| 260 | -0.13732 | -73.4331550802 | 0.187 | 0.3279 | 0.024 | 22513 | 0.13099749 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.